FRI0499 Real-world study on the patterns and cost of treatment failure in patients with psoriatic arthritis using us claims data
Karen Price(Purchase College), Swapna Goday, Vamshi Ruthwik Anupindi, Leah Burns(Bristol-Myers Squibb (Germany)), E. Alemao(Bristol-Myers Squibb (Sweden)), Zhenyu Guo(Bristol-Myers Squibb (Germany))
Cited by 1
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96